Regeneron Pharmaceuticals Inc (REGN) — Analysis Summary
Regeneron Pharmaceuticals Inc (REGN) has a market cap of $68.79B with year-over-year revenue growth of +1.0%. Net margin stands at 31.4%. The stock trades at a P/E ratio of 15.6.
Key Takeaways
- Revenue changed +1.0% year-over-year
- Net margin of 31.4%
- P/E ratio of 15.6
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, REGN posted revenue growth of +1.0% and trades at a P/E of 15.6.
Regeneron Pharmaceuticals Inc (REGN)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Operating margin (24.3%) exceeds gross margin (0.0%) — check for other operating income or data classification issues
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
15,410
Headquarters
TARRYTOWN, NY
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$3.76
Dividend Yield
0.57%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.